{"id":"tetrabenazine-withdrawal","safety":{"commonSideEffects":[{"rate":null,"effect":"Rebound chorea"},{"rate":null,"effect":"Rebound akathisia"},{"rate":null,"effect":"Worsening involuntary movements"}]},"_chembl":{"chemblId":"CHEMBL117785","moleculeType":"Small molecule","molecularWeight":"317.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tetrabenazine depletes monoamines (dopamine, serotonin, norepinephrine) by inhibiting VMAT2, thereby reducing involuntary movements in hyperkinetic disorders. Upon withdrawal, sudden restoration of monoamine signaling can cause rebound worsening of chorea, akathisia, or other movement abnormalities. This is a recognized clinical phenomenon requiring careful tapering rather than abrupt discontinuation.","oneSentence":"Tetrabenazine withdrawal refers to the clinical syndrome that occurs when tetrabenazine (a vesicular monoamine transporter inhibitor) is discontinued, characterized by rebound hyperkinetic movement disorders.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:11:59.275Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Management of tetrabenazine discontinuation syndrome to prevent rebound hyperkinetic movement disorders"}]},"trialDetails":[{"nctId":"NCT01834911","phase":"PHASE4","title":"Effect of Tetrabenazine on Stroop Interference in HD","status":"COMPLETED","sponsor":"New York Medical College","startDate":"2013-03","conditions":"Huntington Disease","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":33,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Tetrabenazine withdrawal","genericName":"Tetrabenazine withdrawal","companyName":"New York Medical College","companyId":"new-york-medical-college","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tetrabenazine withdrawal refers to the clinical syndrome that occurs when tetrabenazine (a vesicular monoamine transporter inhibitor) is discontinued, characterized by rebound hyperkinetic movement disorders. Used for Management of tetrabenazine discontinuation syndrome to prevent rebound hyperkinetic movement disorders.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}